Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

17.07 -0.99 (-5.51%)

Streaming Delayed Price Updated: 2:10 PM EDT, Sep 18, 2026 Add to My Watchlist

Price and Volume

Volume	1,380,682
Open	18.07
Bid (Size)	17.06 (300)
Ask (Size)	17.07 (300)
Prev. Close	18.06
Today's Range	16.96 - 18.15
52wk Range	11.92 - 27.30
Shares Outstanding	58,310,703
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 17, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

September 08, 2026

Via Chartmill

Performance

YTD	-7.8%	-7.8%
1 Month	-34.4%	-34.4%
3 Month	-13.8%	-13.8%
6 Month	-4.1%	-4.1%
1 Year	+29.8%	+29.8%

More News

These stocks are moving in today's pre-market session ↗

September 08, 2026

Via Chartmill

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings

September 08, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

September 03, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

July 29, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

July 28, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

July 23, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock

July 21, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

July 21, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

July 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? ↗

July 04, 2026

Via The Motley Fool

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗

July 01, 2026

Via The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 26, 2026

Via The Motley Fool

Dyne Therapeutics Appoints Barry Greene to Board of Directors

June 22, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 18, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

June 17, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

June 03, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

Via The Motley Fool

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Via The Motley Fool

Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

May 26, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2026

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?

Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?

Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?

The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market

What is the current price of Dyne Therapeutics, Inc. - Common Stock?

The current price of Dyne Therapeutics, Inc. - Common Stock is 17.07

When was Dyne Therapeutics, Inc. - Common Stock last traded?

The last trade of Dyne Therapeutics, Inc. - Common Stock was at 09/18/26 02:10 PM ET

What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?

The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 995.07M

How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?

Dyne Therapeutics, Inc. - Common Stock has 995M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.